Toward Exosome-Based Therapeutics: Isolation, Heterogeneity, and Fit-for-Purpose Potency

1The intracellular transfer of diverse moieties via extracellular vesicles (EVs) has been proposed to be a widespread process. Cells release diverse EVs that include exosomes, microvesicles (MVs) and apoptotic bodies. The classification of such EV subtypes is mainly based on their biogenesis and resultant biophysical properties, such as size, density, and predominant protein markers. Originally, the class of EVs generated through the endosomal pathway (exosomes) was assumed to represent a mere mechanism for the cell to jettison unwanted moieties. We now understand that exosome biogenesis is a process governed by the endosomal-sorting complex machinery and involves the formation of intraluminal vesicles within multivesicular bodies (MVBs). Mature MVBs fuse with the plasma membrane and subsequently secrete the enclosed exosomes into the extracellular environment. During their biogenesis, exosomes associate with an array of bioactive cargo from their parental cell. Such cargo has been reported to include genetic information in the form of small noncoding RNAs, free fatty acids, surface receptors, and proteins (Figure 1). It is considered that the biophysical properties of EVs, including their cargo, reflect the stimulus triggering their formation, implying specific packaging of “message” prior to export from the parent cell. In turn, the secretion of these biologically loaded signaling vectors to the extracellular environment represents an important method of cell-to-cell communication, dubbed the “new endocrinology”.

2Exosomes have been shown to play important roles in a broad range of pathological conditions, such as cancer, liver and kidney disease, neurodegenerative disorders, and numerous cardiopulmonary disorders. More recently, in addition to their prognostic and diagnostic value, exosomes have also been reported to represent novel therapeutic reagents across multiple disciplines.

3The therapeutic capacity of exosomes generated by mesenchymal stem/stromal cells (MSCs) that have been derived from different organs, such as bone marrow, umbilical cord, adipose tissue, or placenta has been tested in various disease models. In the cases where cells and their respective exosomes were studied in parallel, exosome treatment has demonstrated a similar or even superior therapeutic capacity to MSC treatment. MSC-exosomes have provided beneficial effects in numerous disease models promoting functional recovery and neurovascular plasticity following traumatic brain injury, reducing myocardial infarction size, ameliorating hypoxia-induced pulmonary hypertension, aiding repair of kidney injury, and orchestrating neurological protection by the transfer of microRNA. MSC-exosome-based approaches for the treatment of different disease models are highlighted in Table 1.

4While the functional roles of exosomes have been extensively reported [reviewed in Ref.], few reviews have addressed the challenges underlying the transition of exosome-based therapies from animal models to clinical development. Furthermore, the full realization of their therapeutic potential has been hampered by a lack of standardization in exosome isolation and characterization. Herein, we will focus on the therapeutic application of MSC-exosomes and outline topics relevant to the facilitation of their development as a pharmaceutical preparation, focusing on exosome harvesting, dosing and potency, and providing guidance on the current challenges in bringing exosome-based therapies to clinic.

5A comprehensive characterization of the tissue/cellular source of exosomes is imperative for exosome-based therapeutics. Detailed methods for obtaining human MSCs from several tissues, including bone marrow (BMSCs), Wharton’s jelly (WJMSCs), umbilical cord blood, and adipose tissue are well reported. By definition, MSCs must adhere to plastic, demonstrate a baseline differentiation potential to osteocytes, chondrocytes, and adipocytes in vitro, and express the presence of widely accepted surface markers (Table 2). However, donor-to-donor variability remains a prominent challenge. Studies have found that BMSCs obtained from older donors have slower proliferation and reduced differentiation potential in vitro. Furthermore, discrepancies in the differentiation capacity and transcriptome profiles are reported to be tissue and species dependent. To what extent do these uncertainties affect the therapeutic capacity of MSCs and their resultant exosomes remains unclear. Thus, in addition to validated MSC isolation procedures, investigators should adhere to carefully selected donor eligibility criteria in accordance with the appropriate ethical and regulatory approval, employing strict control measures to prevent risk of relevant communicable disease agents or diseases (RCDADs), such as human immunodeficiency virus (HIV), hepatitis C virus, and cytomegalovirus. Moreover, donor screening should include a comprehensive medical record review, physical assessment, and medical history interview, with records documented in compliance with appropriate regulatory frame. The International Society of Extracellular Vesicles (ISEV), the Food and drug Administration (FDA), the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use, and the European Medicines Agency (EMA) provide extensive guidance for the development and generation of novel biological medicines with regard to donor/patient care, product safety, and quality. The demonstration that exosomes generated by MSCs isolated from WJMSCs are as effective as BMSC-exosomes in treating rodent disease models may facilitate standardization and consistency of MSC lines for exosome harvesting. Moreover, the umbilical cord may possess several advantages over bone marrow. First, the umbilical cord represents a more readily available source than bone marrow. Second, it is often viewed as discarded medical waste that does not require any invasive procedures or cadaver procurement.

6Previous studies have reported that the protein and RNA profile of exosomes reflect the cell culture conditions and microenvironmental stimuli that triggered their release. With this in mind, it begs to question can “stimulating” and/or preconditioning cells be used as a means to generate a more homogenous or efficacious exosome population? Interestingly, in an experimental model of hyperoxia-induced bronchopulmonary dysplasia (BPD), Waszak and coworkers found that the conditioned media (CM) derived from hyperoxia-preconditioned rat BMSCs (95% O2, for 24 h) provided greater protection in vivo compared to CM collected from cells grown under control conditions. Clearly, in the absence of further characterization, one can only speculate where the observed augmentation of activity resides. Other studies have found that MSCs cultured in hypoxia conditions (<5% O2) exhibited an altered protein expression pattern compared to MSCs cultured in the so-called “normoxia”. Furthermore, in a murine hind limb ischemia model, they showed that intra-arterial injection of MSCs cultured in both “normoxic” or hypoxic conditions enhanced revascularization compared with saline controls; however, the functional recovery of mice that received hypoxia preconditioned MSCs was faster. These reports suggest that preconditioning MSCs in different oxygen environments may improve their tissue regenerative potential.

7Indeed, “hypoxia” (1% O2) has been shown to increase exosome production in numerous cell types in vitro. Previous studies have shown that the hypoxia-induced elevation in exosome secretion is chiefly governed by hypoxia-inducible factor-1 alpha (HIF-1α) and is independent of apoptosis. Often, laboratory cell culture conditions are at atmospheric oxygen levels (21% O2, corresponding to a PO2 of ~159 mmHg); following adjustment to 5% CO2, this equates to ~19.95% O2 (~150 mmHg). Although, it is challenging to accurately measure tissue oxygen concentrations in vivo, it is well recognized that most of the human body tissue is normally exposed to much lower O2 levels. This can range from 160 to 100 mmHg in the alveoli, >35 mmHg in the brain, and ~25 mmHg in skeletal muscle. Notably, in the bone marrow, arguably the most common origin of MSCs, the PO2 is reported to be ~40 mmHg, while the umbilical cord vasculature PO2 is reported to be between 10 and 30 mmHg. Organ oxygen levels have been extensively reviewed. However, it is important to remember that the different techniques used to measure oxygen concentration in vivo are subject to their own advantages and limitations.

8In vivo, the oxygen concentration of an organ is an indication of its physiological state and reflects the balance between oxygen delivery and its metabolic consumption. Consequently, in a physiological condition, organs are subject their own unique “physioxia” status. On balance, the routine laboratory cell culture conditions expose MSCs to oxygen levels higher than those in their physiologic niches, and this departure from “physioxia” may precipitate a “perceived hyperoxia” response. Thus, it is important to recognize this factor when interpreting results of experiments performed in atmospheric “normoxia,” and also to realize that the impact of this factor may vary, depending on the particular study and the metrics assessed.

9In turn, several questions remain unanswered. The optimal oxygen concentration for in vitro MSC culture and the effect that it may have on subsequent exosome production remains undefined at this point. Existing reports indicate that optimization is likely to be both MSC origin and disease model specific. Thus, additional studies assessing the effect of oxygen levels on MSCs and their resultant exosomes are much needed.

10Cells generate three major EV classes: apoptotic bodies, MVs, and exosomes. Arguably, it is often assumed each subtype represents a homogenous vesicle population that can be distinguished based on biophysical properties such as size or density. However, it has become obvious that even within such subtypes, there is heterogeneity. Although, the field lacks tools to distinguish vesicles from different routes of biogenesis, recent evidence has demonstrated that MSCs release distinct EV subpopulations that differ in biophysical, proteomic, and RNA repertoires. Specifically, Kowal and coworkers found that large-, medium-, and small-sized EVs can be isolated by sequential low-, intermediate-, and high-speed centrifugation, respectively. Among the small-EVs (exosomes), four subcategories were defined by their degree of enrichment in CD63, CD9, and/or CD81 tetraspanins. In accordance, Lai et al. found that MSCs secrete many distinct subtypes of vesicles, which differ in RNA and protein composition. It is relevant to note that the study involved an immortalized, iPS-derived MSC cell line that will likely secrete a more restricted range of exosome subtypes than those generated by primary cells.

11In our hands, ongoing studies aim to address the relationships between MSC-exosome subtypes and therapeutic efficacy and to explore the hypothesis that a discrete subtype is responsible for the therapeutic activity in our established experimental models of BPD, a chronic lung disorder of infants. Here, we isolated exosomes from either human BMSCs or WJMSCs by differential centrifugation, followed by tangential flow filtration and iodixanol density floatation before separating exosome subtypes by size-exclusion chromatography (SEC) (described in Figure 2). This approach separates MSC-exosome subtypes based on their size, and in accordance with previous reports, we demonstrate a shift in protein markers associated with different exosome subtypes. Specifically, we found that CD63 and flotillin-1 (FLOT1) is associated with “large”-exosomes (>80 nm), while Alix and TSG101 is enriched in “small”-exosomes (<80 nm). Few studies assess the ratio of such markers; however, further investigation is warranted as it may provide a tool for distinguishing exosome subtypes. Ongoing in vivo studies are testing whether the different MSC-exosome subtypes exhibit differential therapeutic efficacy in a number of animal models currently utilized by our group and collaborators.

12Regulatory frameworks often require a mechanism-of-action that details the identity, quantification, and characterization of such bioactive substances responsible for the therapeutic effect(s). Moreover, disclosure of non-active components (“excipients”) in drug preparations should be acknowledged. Knowing exosome subtypes harbor different protein and genetic cargo, it is fair to speculate that they likely mediate different effects on targets cells. Thus, improved separation techniques that distinguish between “non-active” and therapeutic exosome subtypes may help focus the search for the bioactive substance(s) responsible for such beneficial effects. The “one size fits all” hypothesis may not work for exosome-based therapeutics. Although a specific exosome subset may induce beneficial therapeutic effects in a specific disease model, it is important to recognize that a different exosome subpopulation may afford the beneficial effects in a different disease model.

13Isolation methods impact exosome integrity, in vivo biodistribution and metabolic fate. Exosome isolation techniques from various biological fluids and cell culture medium have been extensively reviewed. It is well established that widely applied exosome isolation techniques, such as differential ultracentrifugation (UC), promote vesicle aggregation and often co-isolate soluble factors and protein. Thus, a consensus in the field has shifted toward more “gentle” isolation techniques to ultimately reduce contaminants (non-EV material), maintain integrity, and isolate “bioactive” vesicles from heterogeneous EV populations. To date, popular avenues of investigation include gradient density isolation and SEC, with the latter being more suited to enclosed tissues culture systems. Variations of such approaches have been shown to effectively separate exosomes from proteins and soluble factors in different biological fluids. However, layered density-based procedures may achieve enrichment rather than true exosome isolation, where the influence of UC parameters coupled with high-sucrose concentrations may change the osmotic environment. Furthermore, UC methods are impracticable for large-scale bioprocessing.

14Several emerging technology platforms have shown promise in isolating exosomes from various sample matrices, with each method exploiting a particular biophysical trait of exosomes such as their size, density, shape, or surface receptors (Figure 3). The final goal is an isolation method that is label free, distinguishes between exosome subtypes and interfering components, and can facilitate a large-scale production of exosomes.

15Recently, Lee and colleagues employed a label-free acoustic nano-filter system to isolate exosomes based on their size. Specifically, using ultrasound standing waves exert differential acoustic force, they isolated exosomes from both cell culture media and stored red blood cell products. They effectively separated exosomes (149 nm) and MVs (410 nm). Although, its application for high-throughput exosome preparations is yet to be established, previous studies have used label-free acoustic wave systems to isolate circulating tumor cells.

16Exosomes can also be separated by size with 10 nm accuracy using variations of flow field-flow fractionation (F4). Asymmetrical F4 (AF4) is a one-phase chromatography method that uses parabolic-flow to drive exosomes across a flow channel. A crossflow intercepts the parabolic-flow perpendicular to the channel and distributes particulate components against the flow chamber wall. Subsequently, exosomes are separated based on differences in diffusivity. Smaller particles diffuse further from the accumulation wall and are eluted earlier than larger ones. Successful attempts have been made using AF4 to isolate exosomes from human neural stem cell culture and melanoma cell lines. AF4 approaches provide promise for “label-free” isolation of large-scale exosome production.

17To effectively utilize the size difference between exosomes, other EV subtypes and cellular debris, Wang and colleagues fabricated a porous silicon nanowire-on-micropillar “nano-trap” made from ciliated micropillars. This fabricated microfluidic device preferentially traps exosomes with a diameter of 40–100 nm, while filtering out proteins, larger EVs, and cellular debris. Moreover, trapped exosomes can be recovered by dissolving the porous silicon nanowires in PBS buffer. However, in this proof-of-concept study, the authors noted poor vesicle retention (~60%) and only assessed small sample volume (30 μl), thus scalability is yet to be demonstrated.

18Overall, to support the development of exosome-based therapeutics, research efforts should focus on the development of “label-free” exosome isolation techniques that can support high-throughput systems/scale-up requirements and are capable of distinguishing exosome subtypes. Although a number of highly sophisticated technologies for EV isolation have emerged recently, their application is mainly in the biomarker field, as tools for exosome-based diagnostics. Although such emerging technologies hold great promise, the large-scale preparation of isolated exosome subtypes to be used as the basis of exosome-based pharmaceutical products will probably depend, at least in the near future, on modifications of classic industrial processes such as SEC.

19Currently, investigators use several different methods to quantify exosome dosage, making inter-study comparison troublesome. Common quantitative practices include reporting cell equivalents, protein concentration, and/or specialized quantitative analytical measurements by instruments, such as tunable resistive pulse sensing (TRPS) and nanoparticle tracking analysis (NTA), with each method harboring its own advantages and limitations [for recent reviews]. The need to standardize exosome dosing is imperative. Of interest, methods such as TRPS are currently used to verify particle size and characterization for liposome-encapsulated forms of doxorubicin and are accepted within the definition of bioequivalence as set forth by the FDA and EMA. Although enumeration of analytical criteria is beyond the scope of this review, we acknowledge that the field is limited by current technology and lacks the ability to accurately assess exosomes at a single vesicle level. Thus, to aid inter-study comparison, we recommend that in addition to providing extensive detail of standardized cell culture conditions and pre-analytical protocols, investigators should measure exosome concentration using multiple quantification tools, where possible. A summary of the advantages and limitations of common methods used to determine exosome dose are highlighted in Table 3. Establishing an exosome potency assay is a novel approach which holds great promise in standardizing exosome dosing.

20The definition of the bioactive substance(s) will remain a crucial question in the preclinical development of exosome-based therapeutics. With an orchestra of bioactive cargo and diverse physiological effects (Figure 1B), identification of “one” bioactive substance or a singular mechanism-of-action appears improbable. By FDA standards, potency is defined as the products specific ability or capacity to affect a given result. With no “gold-standard” technique for their quantification, assessment of exosome potency would be a valuable tool in overcoming the inconsistencies in preparations and batch-to-batch variation. For example, exosomes obtained from two separate donors may be normalized via a given quantitative method; however, the “bioactive” load may differ, subsequently the potency and degree of efficacy will not be the same. Thus, investigators should consider employing a unique exosome potency unit (EPU) to standardize practices and minimize variation between different samples. Presently, attempts to define an exosome potency metric utilized the immunomodulatory properties of MSC-exosomes. For example, Jiao et al. described an in vitro potency assay for MSC-exosomes based on the release of IL-10 from mononuclear cells following incubation with exosome preparations, and other studies have shown that T-cell proliferation assays may be modified to provide the basis for assays on exosome immunomodulatory potency. Growing evidence also suggests that MSC-exosomes can modulate macrophage phenotypes. Macrophages play a pivotal part in regulating immune responses. They assume both phagocytic “defensive” roles and exhibit regulatory “anti-inflammatory” actions, facilitating both the initiation and the resolution of inflammation. With this consideration in mind, our ongoing studies are exploring an in vitro macrophage polarization assay as a means of assessing MSC-exosome potency. Briefly, the potency assay involves adding MSC-exosomes to murine bone marrow-derived macrophages (BMDMs) that are polarized to the classically activated (proinflammatory) M1-phenotype. The functional endpoint is the capacity of MSC-exosomes to suppress the mRNA induction of TNFα. The half maximal effective concentration (EC50 value, 50% inhibition in TNFα mRNA levels, relative to M1 control) is transformed to an arbitrary EPU (described in Figure 4). In turn, an EPU could potentially be applied to standardize dosing between different exosome preparations. In all cases, potency assays need to be disease specific, fit-for-purpose, and employ relevant functional end-points.

21In 2002, Lamparski et al. described a method for the production and characterization of clinical grade exosomes derived from dendritic cells for their application in cancer vaccine clinical trials. Using ultrafiltration coupled with a sucrose/deuterium oxide UC cushion, they isolated vesicles (50–90 nm in diameter) containing major histocompatibility complex (MHC) class-I, -II, and CD1, and tetraspanin molecules (CD9, CD63, and CD81) In addition, in 2005, Navabi and coworkers detailed the development of a method for the preparation and characterization of good manufacturing practice (GMP)-grade exosomes from the ascites fluid of ovarian cancer patients. Since then our understanding of exosome biology has improved and the development of specialized isolation and characterization methods has allowed investigators to more accurately isolate and characterize exosome populations.

22Considering the development of exosome-based therapeutics, lessons could be learned from cell therapy. The in vitro expansion of cells (such as MSCs) is required to deliver an effective therapeutic dose, with the absence of having a detrimental impact on the quality of the cell. Upon scaling-up, process analytical technology (PAT), a system proposed by the FDA, may be implemented to monitor the manufacturing process through continuous measurement of cell parameters. Monitoring bioprocess parameters, such as population doubling time, temperature, metabolite concentrations, pH, pO2 and pCO2, may help ensure optimal exosome quality and quantity, as previous reports have shown that subtle acidic pH shifts may impair exosome aggregation inhibiting forces and, in turn, promote aggregation and reduce functionality.

23Recently, the inevitable shift to using tissue culture bioreactors has been used to generate large-scale EV preparations. Indeed, Watson and colleagues demonstrated that hollow-fiber bioreactors promotes enhanced exosome production (~40-fold greater EVs/ml of CM) when compared to conventional 2D tissue culture preparations. However, it remains unclear if such methods enhance generalized EV production or simply reflect a reduction in exosome re-uptake. Under the considerations discussed above, relating to EV diversity and the possibility that only specific exosome subtypes may represent the therapeutic agent, it is premature to assume that production of higher EV numbers will necessarily yield a higher efficacy final product. Optimization of MSC culture conditions will, therefore, require the parallel development of a dependable and easily adoptable potency assay.

24With evidence to suggest that exosomes can be stored at −20°C for up to 6 months with no loss to their biochemical activity, “off-the-shelf” exosome-based products represent an attractive pharmaceutical formulation. Although standardized storage procedures remain to be defined, current storage protocols use isotonic buffers to prevent pH shifts during storage, avoid freeze–thaw cycles and are absent of dimethyl sulfoxide (DMSO) and glycerol as previous reports have shown these agents may impact exosome integrity. With a lack of data addressing the impact of storage time and excipients on exosome structural stability and functional efficacy, more studies are warranted to help define a provisional “shelf-life” for exosome-based products and facilitate the manufacturing and distribution process.

25Promising preclinical data that demonstrated dendritic cell-derived EVs containing MHC–peptide complexes could alter tumor growth in immune competent mice led to a phase I anti-melanoma clinical trial conducted in France and a phase I anti-non-small cell lung cancer clinical trial in the United States (clinical trial applications highlighted in Table 4). Both clinical trials administered autologous dendritic cell-derived EVs that met their respective current GMP standards. Such clinical trials to date are important for their demonstration of both the feasibility and the short-term safety of autologous EV administration, but safety considerations for therapies based on exogenous exosome-based products will arguably be more stringent. Nevertheless, it is very encouraging to note that preclinical studies have established immunomodulation as the main therapeutic mechanism of MSC-exosomes action. Immunomodulation is clearly involved in the autologous exosome clinical trials mentioned above, and this may provide guidelines and precedent for clinical trials using exogenous exosomes. In this context, a recent clinical case involving treatment of a steroid-refractory graft-vs-host disease patient with MSC-EVs derived from unrelated bone marrow donors produced encouraging results.

26Ultimately, issues raised in this review aim to provide a basic guidance for investigators on key issues to consider for the smooth transition of exosome-based therapies from the preclinical model into clinical development (Figure 5). Among them, determining the optimal dose, the appropriate time window for exosome administration, the number of doses, and route of administration that achieves maximal efficacy without adverse effects are the most important issues to resolve. Such issues will be disease/model specific and clearly beyond the scope of this work.

27Exosome-based therapeutics represent a most promising next generation approach for treating a diverse number of diseases, particularly diseases the pathogenesis of which involves a primary (or major) inflammatory component. The efficacy of MSC-exosome treatments has been robustly established in numerous preclinical models, but development of large-scale GMP-grade exosome-based pharmaceuticals and subsequent clinical trials demand the resolution of several technological and mechanistic issues, reflecting the cautious navigation in unknown seas for this relatively novel field. Among the major issues to be resolved are the definition of an EPU, the standardization of MSC culture conditions and protocols for exosome harvest and storage. Although safety considerations need also to be addressed, it is expected that safety concerns for cell-free, exosome-based clinical trials will be arguably milder than those relevant to live cell MSC trials currently in progress, as mutagenicity and oncogenicity concerns will be null.

28GW participated in data collection, analysis, and manuscript writing. SK and SAM contributed to final article editing and approval.

29The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.